These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 29790581)

  • 1. The pharmacokinetics, pharmacodynamics and tolerability of PUR0200, a novel tiotropium formulation, in chronic obstructive pulmonary disease.
    Singh D; Ravi A; Kane K; Schmalbach T; Hava DL
    Br J Clin Pharmacol; 2018 Sep; 84(9):2097-2105. PubMed ID: 29790581
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Particle size and gastrointestinal absorption influence tiotropium pharmacokinetics: a pilot bioequivalence study of PUR0200 and Spiriva HandiHaler.
    Perry J; Trautman B; Takher-Smith J; Kramer S; Kane K; Silverman M; Tan L; Haughie S; Richter W; Kirkov V; Arsova S; Ward J; Hava DL
    Br J Clin Pharmacol; 2019 Mar; 85(3):580-589. PubMed ID: 30521129
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In Vitro, Pharmacokinetic, Pharmacodynamic, and Safety Comparisons of Single and Combined Administration of Tiotropium and Salmeterol in COPD Patients Using Different Dry Powder Inhalers.
    Horhota ST; van Noord JA; Verkleij CB; Bour LJ; Sharma A; Trunk M; Cornelissen PJ
    AAPS J; 2015 Jul; 17(4):871-80. PubMed ID: 25794622
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Tiotropium Safety and Performance in Respimat® (TIOSPIR®) Trial: Spirometry Outcomes.
    Anzueto A; Wise R; Calverley P; Dusser D; Tang W; Metzdorf N; Dahl R
    Respir Res; 2015 Sep; 16(1):107. PubMed ID: 26369563
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tiotropium Respimat(®) Versus HandiHaler(®): Comparison of Bronchodilator Efficacy of Various Doses in Clinical Trials.
    Calverley PM; Könen-Bergmann M; Richard F; Bell S; Hohlfeld JM
    Adv Ther; 2016 May; 33(5):786-93. PubMed ID: 27084728
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bronchodilator efficacy of 18 μg once-daily tiotropium inhalation via Discair
    Yildiz P; Bayraktaroglu M; Gorgun D; Secik F
    Int J Chron Obstruct Pulmon Dis; 2016; 11():2859-2867. PubMed ID: 27920513
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tiotropium bromide. A review of its use as maintenance therapy in patients with COPD.
    Keam SJ; Keating GM
    Treat Respir Med; 2004; 3(4):247-68. PubMed ID: 15350163
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A systematic review of comparative studies of tiotropium Respimat® and tiotropium HandiHaler® in patients with chronic obstructive pulmonary disease: does inhaler choice matter?
    Dahl R; Kaplan A
    BMC Pulm Med; 2016 Oct; 16(1):135. PubMed ID: 27724909
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dose Determination for a Fixed-Dose Drug Combination: A Phase II Randomized Controlled Trial for Tiotropium/Olodaterol Versus Tiotropium in Patients with COPD.
    Maltais F; Hamilton A; Voß F; Maleki-Yazdi MR
    Adv Ther; 2019 Apr; 36(4):962-968. PubMed ID: 30843141
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bronchodilator efficacy of tiotropium/formoterol (18/12 µg once daily via a Discair inhaler), tiotropium alone (18 µg by Handihaler) or combined with formoterol (12 µg twice daily by Aerolizer) in adults with moderate-to-severe stable COPD.
    Yildiz BP; Bayraktaroglu M; Gunen H
    Curr Med Res Opin; 2019 Dec; 35(12):2187-2196. PubMed ID: 31397184
    [No Abstract]   [Full Text] [Related]  

  • 11. A multicenter, randomized, double-blind dose-ranging study of glycopyrrolate/formoterol fumarate fixed-dose combination metered dose inhaler compared to the monocomponents and open-label tiotropium dry powder inhaler in patients with moderate-to-severe COPD.
    Tashkin DP; Martinez FJ; Rodriguez-Roisin R; Fogarty C; Gotfried M; Denenberg M; Gottschlich G; Donohue JF; Orevillo C; Darken P; St Rose E; Strom S; Fischer T; Golden M; Reisner C
    Respir Med; 2016 Nov; 120():16-24. PubMed ID: 27817811
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fast onset of action of glycopyrronium compared with tiotropium in patients with moderate to severe COPD - A randomised, multicentre, crossover trial.
    Watz H; Mailänder C; May C; Baier M; Kirsten AM
    Pulm Pharmacol Ther; 2017 Feb; 42():13-20. PubMed ID: 27940287
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacodynamic steady state of tiotropium in patients with chronic obstructive pulmonary disease.
    van Noord JA; Smeets JJ; Custers FL; Korducki L; Cornelissen PJ
    Eur Respir J; 2002 Apr; 19(4):639-44. PubMed ID: 11998992
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tiotropium and olodaterol fixed-dose combination versus mono-components in COPD (GOLD 2-4).
    Buhl R; Maltais F; Abrahams R; Bjermer L; Derom E; Ferguson G; Fležar M; Hébert J; McGarvey L; Pizzichini E; Reid J; Veale A; Grönke L; Hamilton A; Korducki L; Tetzlaff K; Waitere-Wijker S; Watz H; Bateman E
    Eur Respir J; 2015 Apr; 45(4):969-79. PubMed ID: 25573406
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacodynamics, pharmacokinetics and safety of revefenacin (TD-4208), a long-acting muscarinic antagonist, in patients with chronic obstructive pulmonary disease (COPD): Results of two randomized, double-blind, phase 2 studies.
    Quinn D; Barnes CN; Yates W; Bourdet DL; Moran EJ; Potgieter P; Nicholls A; Haumann B; Singh D
    Pulm Pharmacol Ther; 2018 Feb; 48():71-79. PubMed ID: 28987804
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The 24-h lung-function profile of once-daily tiotropium and olodaterol fixed-dose combination in chronic obstructive pulmonary disease.
    Beeh KM; Westerman J; Kirsten AM; Hébert J; Grönke L; Hamilton A; Tetzlaff K; Derom E
    Pulm Pharmacol Ther; 2015 Jun; 32():53-9. PubMed ID: 25956072
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The efficacy of tiotropium administered via Respimat Soft Mist Inhaler or HandiHaler in COPD patients.
    van Noord JA; Cornelissen PJ; Aumann JL; Platz J; Mueller A; Fogarty C
    Respir Med; 2009 Jan; 103(1):22-9. PubMed ID: 19022642
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics and pharmacodynamics of tiotropium solution and tiotropium powder in chronic obstructive pulmonary disease.
    Hohlfeld JM; Sharma A; van Noord JA; Cornelissen PJ; Derom E; Towse L; Peterkin V; Disse B
    J Clin Pharmacol; 2014 Apr; 54(4):405-14. PubMed ID: 24165906
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tiotropium bromide, a new long-acting antimuscarinic bronchodilator: a pharmacodynamic study in patients with chronic obstructive pulmonary disease (COPD). Dutch Study Group.
    Maesen FP; Smeets JJ; Sledsens TJ; Wald FD; Cornelissen PJ
    Eur Respir J; 1995 Sep; 8(9):1506-13. PubMed ID: 8575576
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of aclidinium bromide 400 μg twice daily compared with placebo and tiotropium in patients with moderate to severe COPD.
    Fuhr R; Magnussen H; Sarem K; Llovera AR; Kirsten AM; Falqués M; Caracta CF; Garcia Gil E
    Chest; 2012 Mar; 141(3):745-752. PubMed ID: 21903737
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.